Total submissions: 5
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Labcorp Genetics |
RCV001556723 | SCV000289488 | uncertain significance | not provided | 2025-01-23 | criteria provided, single submitter | clinical testing | This sequence change replaces valine, which is neutral and non-polar, with methionine, which is neutral and non-polar, at codon 240 of the POLE protein (p.Val240Met). This variant is present in population databases (rs371882716, gnomAD 0.01%). This variant has not been reported in the literature in individuals affected with POLE-related conditions. ClinVar contains an entry for this variant (Variation ID: 240624). An algorithm developed to predict the effect of missense changes on protein structure and function (PolyPhen-2) suggests that this variant is likely to be disruptive. In summary, the available evidence is currently insufficient to determine the role of this variant in disease. Therefore, it has been classified as a Variant of Uncertain Significance. |
Gene |
RCV001556723 | SCV001778354 | uncertain significance | not provided | 2023-09-27 | criteria provided, single submitter | clinical testing | In silico analysis supports that this missense variant does not alter protein structure/function; Has not been previously published as pathogenic or benign to our knowledge; This variant is associated with the following publications: (PMID: 23525077, 26251183, 29273096) |
Center for Genomic Medicine, |
RCV002465597 | SCV002761021 | uncertain significance | not specified | 2023-08-15 | criteria provided, single submitter | clinical testing | |
Clinical Genetics Laboratory, |
RCV001556723 | SCV005197246 | uncertain significance | not provided | 2024-01-23 | criteria provided, single submitter | clinical testing | |
Fulgent Genetics, |
RCV005008202 | SCV005633768 | uncertain significance | Colorectal cancer, susceptibility to, 12; Facial dysmorphism-immunodeficiency-livedo-short stature syndrome; Intrauterine growth retardation, metaphyseal dysplasia, adrenal hypoplasia congenita, genital anomalies, and immunodeficiency | 2024-02-29 | criteria provided, single submitter | clinical testing |